'Evidence summaries: new medicines' help commissioners, budget holders and groups such as Area Prescribing Committees make informed decisions and aid local planning on the introduction of key new medicines.

They are quality-assured summaries of the best available evidence for selected new medicines, or existing medicines with new indications or a new formulation, considered to be of significance to the NHS. The medicines selected have recently been introduced in the UK, or may be introduced in the UK in the next 6-12 months.

The strengths and weaknesses of the relevant evidence are critically reviewed, and a value assessment of each medicine is made based on its safety, effectiveness, patient factors and resource implications, but the ‘Evidence summaries: new medicines' are not formal NICE guidance.

The NHS Constitution gives patients the right to expect that decisions about the funding of medicines and treatments will be made rationally following a proper consideration of the evidence. Where there is no guidance from NICE, these summaries help to ensure consistent access to evidence for decision-makers.


More information

Our integrated process statement sets out how we select topics and prepare the summaries.